Gossamer Bio (GOSS) Assets (2018 - 2026)

Gossamer Bio has reported Assets for 9 years, with the latest figure at $76.9 million in Q2 2026.

• On a quarterly basis, Assets fell 68.1% year-over-year to $76.9 million in Q2 2026; TTM through Jun 2026 was $76.9 million, a 68.1% decrease from a year earlier, with the FY2025 full-year figure at $172.2 million, down 45.37% from the prior year.
• Assets was $76.9 million for Q2 2026 at Gossamer Bio, down from $128.9 million in the prior quarter.
• The five-year high for Assets was $373.4 million in Q2 2024, with the low at $76.9 million in Q2 2026.
• Average Assets over 5 years is $255.9 million, with a median of $265.9 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Assets surged 105.48% in 2024, then tumbled 68.1% in 2026.
• Over 5 years, Assets stood at $272.4 million in 2022, then increased by 14.49% to $311.9 million in 2023, then advanced by 1.08% to $315.3 million in 2024, then sank by 45.37% to $172.2 million in 2025, then slumped by 55.37% to $76.9 million in 2026.
• The last three Assets figures came in at $76.9 million (Q2 2026), $128.9 million (Q1 2026), and $172.2 million (Q4 2025), per Business Quant data.